Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

Xilio Therapeutics provided updates on its clinical pipeline and business operations, reporting on a promising Phase 2 trial for vilastobart, a tumor-activated anti-CTLA-4 monoclonal antibody, in ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures -- UDENYCA® net revenue increased 62% year-over-year -- LOQTORZI® net revenue increased 29% quarter-over-qua ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

INNOVENT BIO (01801.HK) is working with a consultant to gauge the interest of global pharmaceutical companies in its self-developed pioneered PD-1/IL-2 Alpha-bias bispecific antibodies fusion ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

XTX501: masked PD-1/IL-2 bispecific XTX501 is a novel, tumor-activated bispecific PD-1/IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function.